NASDAQ:LYRA
Lyra Therapeutics Inc. Stock News
$0.383
+0.0154 (+4.19%)
At Close: May 17, 2024
Lyra Therapeutics to Present at Upcoming Investor Conferences
07:00am, Thursday, 26'th May 2022
WATERTOWN, Mass. , May 26, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained
Lyra Therapeutics: Progress In The Clinic
12:46pm, Wednesday, 18'th May 2022
Phase 3 trials for LYR-210 are underway. LYR-210 has shown an excellent efficacy and safety profile.
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
09:47am, Tuesday, 10'th May 2022
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 41.30% and 114.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc
7 Stocks to Watch for Major Insider Trading Clues
06:31am, Wednesday, 27'th Apr 2022
These seven stocks show varying degrees of insider trading, which can provide a hint regarding each company or fund's performance. The post 7 Stocks to Watch for Major Insider Trading Clues appeared f
Lyra Therapeutics Stock Surges On Equity Raise Of $100M
12:11pm, Friday, 08'th Apr 2022
Lyra Therapeutics Inc (NASDAQ: LYRA) has announced a private placement of approximately $100.5 million. The Company has offered 18.8 million common shares at $4.22 per share and pre-funded warrants
Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients
12:37pm, Monday, 24'th Jan 2022
Lyra Therapeutics Inc (NASDAQ: LYRA) has initiated its Phase 3 ENLIGHTEN I trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS) patients. LYR-210 is designed to be administered
Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences
07:00am, Thursday, 11'th Nov 2021
WATERTOWN, Mass., Nov. 11, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained
Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q3 2021 Results - Earnings Call Transcript
10:20pm, Tuesday, 09'th Nov 2021
Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q3 2021 Results - Earnings Call Transcript
WATERTOWN, Mass., Oct. 4, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained
Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
07:00am, Tuesday, 21'st Sep 2021
LYR-210 is the First Drug-Eluting Product Candidate to Demonstrate Statistically Significant Symptom Improvement for Six Months with a Single Administration in Surgically Naïve Chronic Rhinosinusitis
Results demonstrate XTreo™ technology platform provides targeted and sustained dosing of anti-inflammatory medication
Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07:00am, Tuesday, 07'th Sep 2021
WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sust
New Strong Sell Stocks for August 20th
10:40am, Friday, 20'th Aug 2021
ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.
Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31
07:35am, Tuesday, 17'th Aug 2021
WATERTOWN, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, susta
New Strong Sell Stocks for August 12th
12:25pm, Thursday, 12'th Aug 2021
WKHS, SPCE, PASG, LYRA, and GO have been added to the Zacks Rank #5 (Strong Sell) List on August 12, 2021